Michael Dell, 40. announced that he will be stepping down later this year as CEO of Round Rock-based Dell, Inc. . Kevin Rollins, Mr. Dell’s longtime partner in running Dell Inc., will take over as CEO of the computer company in mid-July while Mr. Dell will remain chairman of the board. This new arrangement is similar to the one that Microsoft Corp adopted in 2000, when Bill Gates became chairman and chief software architect and Steve Ballmer took over as CEO. Mr. Dell founded Dell in May 1984 when he was a 19-year-old just finishing his freshman year at the University of Texas at Austin. When the company went public four years later, Mr. Dell kept the titles of chairman and CEO.
Daily Archives: March 4, 2004
No Mens Rea?
This NY Times article floats the proposition that Barry Bonds and other alleged customers of accused steroid dispensing BALCO were unwitting consumers of steroids.
H’mm.
Meanwhile, this Reason Online piece addresses the issues in the medical community regarding steroid use.
Justice accuses Jenkens & Gilchrist of participating in a fraud
The NY Times reports here today that the Dallas-based law firm Jenkens & Gilchrist is the subject of a Justice Department motion in federal court that seeks to require the firm to disclose the identities of its clients who were sold abusive tax shelters. The government is contending that Jenkens & Gilchrist participated in fraud and should not be allowed to hide the identities of its tax-shelter clients from the Internal Revenue Service. The so-called crime-fraud exception to attorney-client privilege is most often applied to lawyers who represent organized-crime families and drug rings suspected of racketeering, not to tax lawyers suspected of civil or criminal tax fraud. The I.R.S. issued 25 summonses for the names of Jenkens & Gilchrist clients and other information, the firm refused to comply with any of the summons, and now the Justice Department is seeking an order to enforce the summons.
Eisner Overdrive
As one would expect, the LA Times and the NY Times are all over the Walt Disney Company Board’s decision to remove Michael Eisner as chairman of Disney’s board, although he will remain as CEO for the time being. However, as usual, the Wall Street Journal‘s ($) coverage of the developments here, here and here is far superior.
What is ironic about this development is that it was spurred by Comcast‘s lowball takeover bid for Disney, which Mr. Eisner properly opposes and which has not gone well for Comcast (its stock price is down 10% since the takeover bid was announced). The bottom line is that the Disney board’s failure to develop a succession strategy for top management is coming back to haunt them at a critical time for Disney.
Heart developments in the The Medical Center
The Texas Heart Institute and the DeBakey Heart Center in Houston’s Texas Medical Center are two of the best cardiovascular surgical care facilities in the world. Yesterday, the Texas Heart Institute announced that the 12th and only living recipient of an experimental, self-contained mechanical heart called the AbioCor replacement heart underwent surgery to implant the device on Feb. 20 at its facility in Houston. The recipient of the AbioCor replacement heart is in critical but stable condition. This is the fifth patient to receive the device at Texas Heart Institute under the care of Dr. O.H. Frazier, chief of cardiopulmonary transplantation and director of surgical research at the Texas Heart Institute and chief of transplant services at St. Luke’s Episcopal Hospital. The AbioCor clinical trial began in July 2001.
In this related Chronicle article, several of Houston’s leading cardiologists discuss the merits of the increasingly popular “off-bump” heart bypass procedure in which the operation is done “off-pump” — i.e., without circulating the blood of the patient through a heart-lung machine. While some Houston doctors believe that the benefits of minimizing a patient’s recovery time are so great that they use the procedure almost exclusively, other surgeons are skeptical about the procedure’s ability to reduce the risk of stroke and other side effects.